From the Journals

Risk models fail to predict lower-GI bleeding outcomes


 

FROM GASTROINTESTINAL ENDOSCOPY


On average, time between admission and colonoscopy was between 2 and 3 days (median, 62.2 hours). In 3 out of 4 patients (77%), etiology of LGIB was confirmed; diverticular bleeding was most common (39%), followed distantly by hemorrhoidal bleeding (15%).

Compared with milder cases, patients with severe bleeding were more likely to stay in the ICU (49% vs. 19%; P less than .0001), have a blood transfusion (85% vs 36%; P less than .0001), and need to remain in the hospital for a longer period of time (6 days vs. 4 days; P = .0009). These findings exemplify the high level of resource utilization required for LGIB and show how severe bleeding dramatically compounds intensity of care.

Further analysis showed that none of the seven risk models were predictive across all outcomes; however, some predicted specific outcomes better than others. Leaders were the Glasgow-Blatchford score for blood transfusion (AUC 0.87; P less than .0001), the Oakland score for severe bleeding (AUC 0.74; P less than .0001), the Sengupta score for ICU stay (AUC 0.74; P less than .0001), and the Strate score for both recurrent bleeding during hospital stay (AUC 0.66; P = .0008) and endoscopic intervention (AUC 0.62; P = .01).

The investigators noted that the Glasgow-Blatchford score, which also is used in cases of UGIB, has previously demonstrated accuracy in predicting blood transfusion, as it did in the present study, suggesting that, “[i]n instances where there may be uncertainty of the origin of the bleeding, the Blatchford score may be a preferential choice of risk score.”

“Overall, we found that no singular score performed best across all the outcomes studied nor did any score have an extremely strong discriminatory power for any individual variable,” the investigators wrote, concluding that “... simpler and more powerful prediction tools are required for better risk stratification in LGIB.”

The investigators reported no financial support or conflicts of interest.

*This story was updated on Jan. 31, 2019.

SOURCE: Tapaskar N et al. Gastrointest Endosc. 2018 Dec 18. doi: 10.1016/j.gie.2018.12.011.

Pages

Recommended Reading

Studies support vedolizumab-calcineurin inhibitor combinations but not accelerated infliximab therapy for refractory UC
MDedge Internal Medicine
Childhood inflammatory bowel disease linked to increased mortality
MDedge Internal Medicine
Poor-prognosis cancers linked to highest suicide risk in first year
MDedge Internal Medicine
Postdiagnosis statin use lowers mortality rate for patients with HCC
MDedge Internal Medicine
Low-normal thyroid function tied to advanced fibrosis
MDedge Internal Medicine
Anaerobically prepared donor FMT led to steroid-free remission of ulcerative colitis
MDedge Internal Medicine
FDA approves cabozantinib for previously treated HCC
MDedge Internal Medicine
NIH announces new clinical trial assessing FMT for recurrent CDAD
MDedge Internal Medicine
Diet low in free sugars shows promise for adolescent NAFLD
MDedge Internal Medicine
Perceptions of liver transplantation for ALD are evolving
MDedge Internal Medicine